Sun Pharmaceutical Industries Ltd. benchmarking: Performance to industry peers

Financial

	Sun Pharma. Inds.	Torrent Pharma	Cipla
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	665.0 .	174.0 .	285.0 .
Number of ANDA's Approved By USFDA	548.0 .	132.0 .	230.0 .
Domestic Sales Growth - YoY	14.6 %	11.6 %	7.7 %
US DMF Filings	532.0 .	n/a	2824.0 .
US DMF Approval	402.0 .	n/a	n/a
R&D as a % of Total Sales	5.4 %	4.0 %	7.8 %
Financials
5 yr Average ROE	11.67 %	21.66 %	13.53 %
5yr average Equity Multiplier	1.33	2.73	1.22
5yr Average Asset Turnover Ratio	0.57	0.64	0.77
5yr Avg Net Profit Margin	15.4 %	13.92 %	14.55 %
Price to Book	5.35	18.23	3.38
P/E	38.92	70.68	29.99
5yr Avg Cash Conversion Cycle	-46.88 Days	-145.98 Days	-6.65 Days
Inventory Days	65.22 Days	53.66 Days	57.59 Days
Days Receivable	84.33 Days	45.41 Days	52.05 Days
Days Payable	175.41 Days	270.49 Days	107.59 Days
5yr Average Interest Coverage Ratio	44.12	8.01	68.84
5yr Avg ROCE	18.0 %	23.39 %	19.16 %
5yr Avg Operating Profit Margin	26.44 %	30.55 %	22.76 %
5 yr average Debt to Equity	0.06	0.85	0.02
5yr CAGR Net Profit	30.35 %	22.72 %	9.04 %
5yr Average Return on Assets	8.92 %	8.89 %	11.12 %
Shareholdings
Promoter Holding	54.48 %	68.31 %	29.21 %
Share Pledged by Promoters	1.42 %	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	-2.94 %	-4.34 %
Change in Mutual Fund Holding (3 Yrs)	-0.95 %	-1.92 %	3.66 %

Business

	Sun Pharma. Inds.	Torrent Pharma	Cipla
Product Wise Break-Up	Product Wise Break-Up India Branded Generics 33.0 US Formulations 29.0 Emerging Market 19.0 Western Europe & Other Markets 14.0 Active Pharmaceutical Ingredient (API) 5.0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0 New ventures 0 Pharmaceuticals 0	Product Wise Break-Up New ventures 0 Western Europe & Other Markets 0 Contract Manufacturing 6.15 Active Pharmaceutical Ingredient (API) 0 Brazil 8.98 US Formulations 20.71 Emerging Market 0 Domestic Formulations 42.15 India Branded Generics 0 Pharmaceuticals 0 Germany 13.15 Others 8.86	Product Wise Break-Up New ventures 5.35 Western Europe & Other Markets 0 Contract Manf. 0 Active Pharmaceutical Ingredient (API) 0 Brazil/Latam 0 US Formulations 0 Emerging Market 0 Domestic formulations 0 India Branded Generics 0 Pharmaceutical 94.65 Germany/Europe 0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Central Nervous System (CNS) 19.0 Cardiac Science 17.0 Gastro Intestinal 14.0 Anti - Diabetes 9.0 Pain Management 7.0 Anti-Infective 6.0 Respiratory Systems 5.0 Vitamins / Minerals / Nutrients 5.0 Gynecology 4.0 Dermatology 4.0 Ophthalmology 3.0 Urology 3.0 Anti-infectives 0 Cardiac 0 Gastro Intestinal 0 Antivirals 0 Derma 0 Neuro /CNS 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Opthal/Otologicals 0 Oncology 0 Anti Diabetic 0 Others 4.0	-	Therapeutic Area Wise Break-Up - Domestic Antivirals 0 Gynecology 0 Anti - Diabetes 5.5 Ophthalmology 2.6 Gastro Intestinal 5.5 Gynaec. 0 Pain Management 0 Central Nervous System (CNS) 4.5 Derma 3.5 Urology 5.1 Antineoplast 0 Respiratory Systems 0 Anti-Infective 13.8 Vitamins / Minerals / Nutrients 0 Vitamins 0 Ophthalmology 0 Cardiac Science 11.8 Oncology 0 Anti - Diabetes 0 Anti-Infective 0 Central Nervous System (CNS) 0 Dermatology 0 Cardiac Science 0 Others 47.7
Location Wise Break-Up	Location Wise Break-Up India 33.39 USA 32.68 Emerging Market 19.13 Rest of the World 14.8 Germany 0 Brazil 0 SAGA 0 Europe 0 Global API 0 North America 0	Location Wise Break-Up Rest of the World 0 Emerging Market 0 India 64.69 Europe 0 Global API 0 SAGA 0 Brazil 13.29 Germany 9.73 North America 0 USA 11.57 Others 0.72	Location Wise Break-Up Rest of the World 0 Emerging Market 0 India 46.0 Europe 12.0 Global API 1.0 SAGA 19.0 Brazil 0 Germany 0 North America 22.0 USA 0

Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Financial

Business

SIGN UP FOR FREE